Atlas Trials

Tezacaftor/Ivacaftor Combination Therapy Expanded Access Program for Patients 12 Years of Age and Older With Cystic Fibrosis

Clinical trial NCT03278314 · APPROVED_FOR_MARKETING

Trial details

NCT number
NCT03278314
Sponsor
Vertex Pharmaceuticals Incorporated
Status
APPROVED_FOR_MARKETING
Study type
EXPANDED_ACCESS
Cystic Fibrosis

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.